熱門資訊> 正文
Daiichi Sankyo与General Proximity合作开发肿瘤学目标
2025-11-12 23:40
- Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY) will collaborate with biotech General Proximity to discover and identify new targets for new oncology therapies.
- General Proximity is known for its proximity medicines that the company says can treat so-called previously undruggable targets using its proprietary OmniTAC platform.
- "Induced proximity medicines enable the precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets," according to a press release. "The approach uses small molecules to bring two proteins into close physical proximity and subsequently induce a desired therapeutic effect."
- Deal terms call for General Proximity to use OmniTAC to discover novel effector-target pairs that could eventually be used to develop first-in-class therapeutic candidates.
More on Daiichi Sankyo
- Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript
- Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation
- Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript
- Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer
- AstraZeneca, Daiichi win FDA review for Enhertu label expansion
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。